TY - JOUR T1 - Detection of soluble tumor necrosis factor-p55 levels in the serum and ascitic fluid of patients with hepatocellular carcinoma. AU - Gao,Lei, AU - Bai,Lan, AU - Nan,Qing-Zhen, AU - Yang,Xi-Shan, AU - Chen,Kai, AU - Wen,Han-Ping, AU - Lai,Zhuo-Sheng, AU - Bo,Lin, AU - Zhang,Ya-Li, AU - Zhang,Zhen-Shu, PY - 2002/10/12/pubmed PY - 2002/11/26/medline PY - 2002/10/12/entrez SP - 641 EP - 3 JF - Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA JO - Di Yi Jun Yi Da Xue Xue Bao VL - 22 IS - 7 N2 - OBJECTIVE: To examine soluble tumor necrosis factor receptor-p55 (sTNFR-p55) levels in the serum and ascitic fluid and investigate the significance of this examination in assessment of the clinical status of patients with primary hepatocellular carcinoma (HCC). METHODS: Enzyme-linked immunosorbent assay (ELISA) was used to examine sTNFR-p55 levels in the serum and ascitic fluid in 25 patients with HCC and 25 with liver cirrhosis (LC). RESULTS: sTNFR-p55 levels in the serum and ascitic fluid in patients with HCC were significantly higher than those in patients with LC and controls (P=0.001). No significant difference was found between LC and the control in terms of serum sTNFR-p55 levels (P=0.19). Positive correlation was observed between sTNFR-p55 levels in the serum and in ascitic fluid of patients with HCC and LC (r=1.000, P<0.001). Logistic regression revealed that in patients with HCC, serum sTNFR-p55 levels were positively correlated with TBil and AFP in the peripheral blood (r=0.524, P=0.01 and r=0.234, P=0.03, respectively). CONCLUSIONS: Increased sTNFRs-p55 levels in the serum and ascitic fluid reflect abnormal immune status of the patients with HCC and help predict the development of tumor. SN - 1000-2588 UR - https://www.unboundmedicine.com/medline/citation/12376300/Detection_of_soluble_tumor_necrosis_factor_p55_levels_in_the_serum_and_ascitic_fluid_of_patients_with_hepatocellular_carcinoma_ DB - PRIME DP - Unbound Medicine ER -